Association of prealbumin with risk of abdominal surgery and endoscopic recurrence in Crohn’s disease: A machine learning study

Table 1 Baseline characteristics of the cohort of newly diagnosed Crohn’s disease patients, n (%)/median (interquartile range)

Characteristics	Total cohort	Q1	Q2	Q3	Q4	P value
	1060	265	265	265	265
Demographics						< 0.001
Gender						0.007
Female	274 (25.8)	86 (32.5)	74 (27.9)	59 (22.3)	55 (20.8)
Male	786 (74.2)	179 (67.5)	191 (72.1)	206 (77.7)	210 (79.2)
Smoking						0.674
Yes	216 (20.4)	56 (21.1)	47 (17.7)	56 (21.1)	57 (21.5)
No	844 (79.6)	209 (78.9)	218 (82.3)	209 (78.9)	208 (78.5)
BMI (kg/m2)	18.5 (16.7, 20.9)	18.4 (16.6, 20.8)	18.4 (16.8, 20.9)	18.4 (17.0, 20.8)	18.7 (16.7, 21.1)	0.982
Laboratory tests
WBC (109)	6.44 (5.04, 8.21)	7.07 (5.39, 9.43)	7.35 (5.57, 9.3)	5.91 (4.7, 7.23)	5.92 (4.82, 7.41)	< 0.001
NLR	1.51 (0.8, 3.02)	2.53 (1.32, 5.59)	1.56 (0.80, 3.24)	1.18 (0.64, 2.33)	1.10 (0.68, 2.35)	< 0.001
LMR	4.16 (2.77, 6.55)	4.13 (2.84, 6.59)	4.27 (2.91, 6.35)	4.16 (2.99, 6.18)	4.12 (2.50, 6.66)	0.96
CRP (mg/dL)	1.44 (0.46, 3.94)	5.90 (2.15, 8.91)	2.11 (0.83, 4.32)	0.82 (0.30, 1.68)	0.59 (0.24, 1.32)	< 0.001
Hb (g/dL)	12.1 (10.3, 13.6)	10.3 (8.6, 12.1)	11.8 (10.4, 13.2)	12.4 (10.8, 13.9)	13.5 (11.8, 14.7)	< 0.001
ESR (mm/hour)	21 (9, 43)	44 (26, 59)	25 (13, 44)	14 (7, 30)	11 (6, 21)	< 0.001
PA (mg/L)	194.4 (139.6, 243.2)	101.4 (77.5, 126.2)	168.9 (152.8, 180.5)	215.5 (209.1, 227.1)	264.6 (252.4, 279.9)	< 0.001
ALB (g/dL)	3.7 (3.22, 4.13)	2.53 (1.32, 5.59)	1.56 (0.80, 3.24)	1.18 (0.64, 2.33)	1.10 (0.68, 2.35)	< 0.001
PT (seconds)	12 (11.1, 13)	12.7 (11.7, 13.7)	12.1 (11.4, 13)	11.6 (10.9, 12.3)	11.6 (11, 12.3)	< 0.001
Fg (g/L)	3.7 (2.9, 4.6)	4.31 (3.4, 5.03)	3.8 (3.2, 4.8)	3.31 (2.6, 4.05)	3.2 (2.4, 3.9)	< 0.001
D-dimer (mg/L)	0.33 (0.19, 0.64)	0.57 (0.34, 1.00)	0.34 (0.20, 0.64)	0.28 (0.17, 0.54)	0.26 (0.15, 0.45)	< 0.001
Crohn’s disease related
Montreal classification A						0.86
A1	133 (12.5)	35 (13.2)	34 (12.8)	34 (12.8)	30 (11.3)
A2	788 (74.3)	189 (71.3)	200 (75.5)	197 (74.3)	202 (76.2)
A3	139 (13.1)	41 (15.5)	31 (11.7)	34 (12.8)	33 (12.5)
Montreal classification B						0.074
B1	473 (44.6)	124 (46.8)	123 (46.4)	129 (48.7)	97 (36.6)
B2	346 (32.6)	84 (31.7)	90 (34.0)	78 (29.4)	94 (35.5)
B3	241 (22.7)	57 (21.5)	52 (19.6)	58 (21.9)	74 (27.9)
Montreal classification L						< 0.001
L1	268 (25.3)	55 (20.8)	57 (21.5)	78 (29.4)	78 (29.4)
L2	67 (6.3)	23 (8.7)	28 (10.6)	2 (0.8)	14 (5.3)
L3	711 (67.1)	183 (69.1)	176 (66.4)	182 (68.7)	170 (64.2)
L4	14 (1.3)	4 (1.5)	4 (1.5)	3 (1.1)	3 (1.1)
CDAI						0.205
Remission	133 (12.5)	32 (12.1)	34 (12.8)	39 (14.7)	28 (10.6)
Mild activity	482 (45.5)	113 (42.6)	120 (45.3)	122 (46.0)	127 (47.9)
Moderate activity	392 (37.0)	101 (38.1)	104 (39.2)	95 (35.8)	92 (34.7)
Severe activity	53 (5.0)	19 (7.2)	7 (2.6)	9 (3.4)	18 (6.8)
Perianal abscess						0.336
No	687 (64.8)	184 (69.4)	168 (63.4)	169 (63.8)	166 (62.6)
Yes	373 (35.2)	81 (30.6)	97 (36.6)	96 (36.2)	99 (37.4)
Use of drugs
5-aminosalicylic acid	90 (9.0)	23 (8.7)	18 (6.8)	28 (10.6)	21 (7.9)	0.241
Steroid	152 (14.3)	34 (12.8)	44 (16.6)	34 (12.8)	40 (15.1)	0.365
Immunosuppressant	261 (24.6)	55 (20.8)	70 (26.4)	64 (24.2)	72 (27.2)	0.115
Biological agent	667 (62.9)	153 (57.7)	159 (60.0)	179 (67.5)	176 (66.4)	0.049

BMI: Body mass index; WBC: White blood cells; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; CRP: C-reactive protein; Hb: Haemoglobin; ESR: Erythrocyte sedimentation rate; PA: Prealbumin; ALB: Albumin; PT: Prothrombin time; Fg: Fibrinogen; CDAI: Crohn’s Disease Activity Index.